• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Bacillus Infections - Pipeline Review, H2 2012 Product Image

Bacillus Infections - Pipeline Review, H2 2012

  • ID: 2335291
  • November 2012
  • 21 pages
  • Global Markets Direct

Bacillus Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Bacillus Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bacillus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacillus Infections. Bacillus Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bacillus Infections.
- A review of the Bacillus Infections products under development by companies and universities/research READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 3
List of Figures 3
Introduction 4
REPORT COVERAGE 4
Bacillus Infections Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Bacillus Infections 6
Bacillus Infections Therapeutics under Investigation by Universities/Institutes 8
Early Clinical Stage Products 9
Comparative Analysis 9
Bacillus Infections Therapeutics – Products under Investigation by Universities/Institutes 10
Bacillus Infections – Therapeutics Assessment 11
Assessment by Monotherapy Products 11
Assessment by Route of Administration 12
Assessment by Molecule Type 14
Drug Profiles 16
Culturelle - Drug Profile 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Bacillus Infections Therapeutics – Drug Profile Updates 17
Bacillus Infections – Product Development Milestones 18
Featured News & Press Releases 18
Feb 16, 2012: BARDA Awards Contract Worth Upto $67m For Development Of New Tetraphase Antibiotic 18
May 07, 2011: Cempra To Present Vitro Activity Data On TAKSTA 18
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables
Number of Products Under Development for Bacillus Infections, H2 2012 6
Products under Development for Bacillus Infections – Comparative Analysis, H2 2012 7
Number of Products under Investigation by Universities/Institutes, H2 2012 8
Comparative Analysis by Early Clinical Stage Development, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Assessment by Monotherapy Products, H2 2012 11
Assessment by Stage and Route of Administration, H2 2012 13
Assessment by Stage and Molecule Type, H2 2012 15
Bacillus Infections Therapeutics – Drug Profile Updates 17

List of Figures
Number of Products under Development for Bacillus Infections, H2 2012 6
Products under Development for Bacillus Infections – Comparative Analysis, H2 2012 7
Products under Investigation by Universities/Institutes, H2 2012 8
Early Clinical Stage Products, H2 2012 9
Assessment by Monotherapy Products, H2 2012 11
Assessment by Route of Administration, H2 2012 12
Assessment by Stage and Route of Administration, H2 2012 13
Assessment by Molecule Type, H2 2012 14
Assessment by Stage and Molecule Type, H2 2012 15

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos